• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用背向散射积分分析技术定量评价川崎病冠状动脉壁回声强度。

Quantitative evaluation of coronary artery wall echogenicity by integrated backscatter analysis in Kawasaki disease.

机构信息

Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan.

出版信息

J Am Soc Echocardiogr. 2010 Sep;23(9):938-42. doi: 10.1016/j.echo.2010.06.018. Epub 2010 Jul 24.

DOI:10.1016/j.echo.2010.06.018
PMID:20656453
Abstract

BACKGROUND

Coronary artery wall echogenicity increases on echocardiograms during the acute phase of Kawasaki disease (KD). According to this background, echogenicity of the coronary artery wall in patients with KD is quantified by using integrated backscatter (IB) analysis.

METHODS

IB analysis is a quantitative method for evaluating echogenicity. We examined the value of IB in the wall of the left anterior descending coronary artery and compared it with that in adjacent intracardiac blood as a measure of background. The difference between these values is represented as corrected IB for the coronary artery wall.

RESULTS

Corrected IB for the coronary artery wall was higher in patients with KD than in controls (KD with pre-immunoglobulin therapy vs. controls: 27.4 +/- 5.3 dB vs. 22.0 +/- 3.5 dB, P < .05) and in patients with coronary enlargement after intravenous immunoglobulin (with vs. without coronary enlargement, 29.2 +/- 5.2 dB vs. 24.1 +/- 5.5 dB, P < .05).

CONCLUSION

The magnitude of IB from the coronary artery wall reflects the effectiveness of immunoglobulin therapy. Furthermore, this method and its value might be useful to predict the occurrence of coronary enlargement in patients with KD.

摘要

背景

川崎病(KD)急性期的超声心动图检查可见冠状动脉壁回声增强。基于这一背景,本研究采用背向散射积分(IB)分析对 KD 患者冠状动脉壁回声强度进行定量评估。

方法

IB 分析是一种评估回声强度的定量方法。我们检测了左前降支冠状动脉壁的 IB 值,并将其与相邻心内血液的 IB 值进行比较,以作为背景的测量值。两者的差值即为冠状动脉壁校正 IB(corrected IB for the coronary artery wall,cIB)。

结果

KD 患者的 cIB 高于对照组(接受免疫球蛋白治疗前的 KD 患者 vs. 对照组:27.4±5.3 dB vs. 22.0±3.5 dB,P<0.05),且冠状动脉扩张的 KD 患者的 cIB 高于无冠状动脉扩张的患者(有 vs. 无冠状动脉扩张,29.2±5.2 dB vs. 24.1±5.5 dB,P<0.05)。

结论

冠状动脉壁 IB 值的大小反映了免疫球蛋白治疗的效果。此外,该方法及其价值可能有助于预测 KD 患者发生冠状动脉扩张的可能性。

相似文献

1
Quantitative evaluation of coronary artery wall echogenicity by integrated backscatter analysis in Kawasaki disease.应用背向散射积分分析技术定量评价川崎病冠状动脉壁回声强度。
J Am Soc Echocardiogr. 2010 Sep;23(9):938-42. doi: 10.1016/j.echo.2010.06.018. Epub 2010 Jul 24.
2
Evaluation of echogenicity of the heart in Kawasaki disease.川崎病中心脏回声性的评估。
Eur J Pediatr. 2014 Aug;173(8):1089-93. doi: 10.1007/s00431-014-2296-4.
3
Quantitative evaluation of myocardial fibrosis by cardiac integrated backscatter analysis in Kawasaki disease.川崎病中通过心脏综合背向散射分析对心肌纤维化进行定量评估。
Cardiovasc Ultrasound. 2016 Jan 12;14:3. doi: 10.1186/s12947-016-0046-7.
4
Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome.川崎病初始超声心动图检查中冠状动脉病变的患病率
Arch Pediatr Adolesc Med. 2006 Jul;160(7):686-90. doi: 10.1001/archpedi.160.7.686.
5
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.英夫利昔单抗强化川崎病一线治疗:一项 3 期随机、双盲、安慰剂对照试验。
Lancet. 2014 May 17;383(9930):1731-8. doi: 10.1016/S0140-6736(13)62298-9. Epub 2014 Feb 24.
6
Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).阿那白滞素用于川崎病合并早期冠状动脉异常患儿的I/IIa期试验的原理与研究设计(ANAKID试验)
Contemp Clin Trials. 2016 May;48:70-5. doi: 10.1016/j.cct.2016.04.002. Epub 2016 Apr 11.
7
N-terminal pro-brain natriuretic peptide in acute Kawasaki disease correlates with coronary artery involvement.急性川崎病中N末端前脑钠肽与冠状动脉受累相关。
Cardiol Young. 2015 Oct;25(7):1311-8. doi: 10.1017/S1047951114002431. Epub 2014 Dec 29.
8
Does abciximab promote coronary artery remodeling in patients with Kawasaki disease?阿昔单抗是否促进川崎病患者的冠状动脉重构?
Am J Cardiol. 2010 Jun 1;105(11):1625-8. doi: 10.1016/j.amjcard.2010.01.332. Epub 2010 Apr 21.
9
Usefulness of real-time 3-dimensional echocardiography for the evaluation of coronary artery morphology in patients with Kawasaki disease.实时三维超声心动图在川崎病患者冠状动脉形态评估中的应用价值
J Am Soc Echocardiogr. 2007 Aug;20(8):930-3. doi: 10.1016/j.echo.2007.01.024. Epub 2007 Jun 6.
10
Coronary artery dimensions in febrile children without Kawasaki disease.发热患儿中无川崎病的冠状动脉尺寸。
Circ Cardiovasc Imaging. 2013 Mar 1;6(2):239-44. doi: 10.1161/CIRCIMAGING.112.000159. Epub 2013 Jan 28.

引用本文的文献

1
Examining the Utility of Coronary Artery Lack of Tapering and Perivascular Brightness in Incomplete Kawasaki Disease.探讨冠状动脉无逐渐变细及血管周围亮度在不完全川崎病中的应用价值。
Pediatr Cardiol. 2019 Jan;40(1):147-153. doi: 10.1007/s00246-018-1971-z. Epub 2018 Sep 8.
2
Quantitative evaluation of myocardial fibrosis by cardiac integrated backscatter analysis in Kawasaki disease.川崎病中通过心脏综合背向散射分析对心肌纤维化进行定量评估。
Cardiovasc Ultrasound. 2016 Jan 12;14:3. doi: 10.1186/s12947-016-0046-7.
3
Evaluation of echogenicity of the heart in Kawasaki disease.
川崎病中心脏回声性的评估。
Eur J Pediatr. 2014 Aug;173(8):1089-93. doi: 10.1007/s00431-014-2296-4.